The literature suggests that aggressive prostate tumors frequently demonstrate dysregulation of androgen receptor (AR) signaling, alterations in ETS transcription factors due to TMPRSS2-ERG fusion events, and overexpression of clinically monitored biomarkers such as PCA3. This evidence concerns the gene TMPRSS2 and prostate neoplasm.